Rothschild Asset Management Inc. bought a new stake in Perrigo Company (NYSE:PRGO) during the first quarter, Holdings Channel reports. The firm bought 7,824 shares of the company’s stock, valued at approximately $519,000.
Several other hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in Perrigo Company during the fourth quarter valued at about $1,384,000. Cadence Capital Management LLC raised its stake in Perrigo Company by 2.9% in the fourth quarter. Cadence Capital Management LLC now owns 4,138 shares of the company’s stock valued at $344,000 after buying an additional 115 shares during the last quarter. Wetherby Asset Management Inc. purchased a new stake in Perrigo Company during the fourth quarter valued at about $214,000. Meiji Yasuda Asset Management Co Ltd. raised its stake in Perrigo Company by 6.5% in the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,786 shares of the company’s stock valued at $232,000 after buying an additional 170 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Perrigo Company by 0.4% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,219 shares of the company’s stock valued at $684,000 after buying an additional 36 shares during the last quarter. Hedge funds and other institutional investors own 76.35% of the company’s stock.
Perrigo Company (PRGO) traded up 0.27% during midday trading on Friday, reaching $73.02. 1,765,723 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $72.68 and its 200-day moving average price is $75.49. The stock’s market cap is $10.47 billion. Perrigo Company has a one year low of $65.47 and a one year high of $99.41.
Perrigo Company (NYSE:PRGO) last announced its earnings results on Tuesday, May 30th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.06. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.19 billion. Perrigo Company had a positive return on equity of 11.79% and a negative net margin of 43.81%. The business’s revenue for the quarter was down 11.4% on a year-over-year basis. During the same period last year, the firm posted $1.32 earnings per share. Equities analysts predict that Perrigo Company will post $4.28 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 13th. Shareholders of record on Friday, May 26th were given a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, May 24th. This represents a $0.64 annualized dividend and a yield of 0.88%. Perrigo Company’s payout ratio is -3.90%.
Several analysts have recently issued reports on PRGO shares. Canaccord Genuity started coverage on shares of Perrigo Company in a research note on Tuesday, February 21st. They issued a “buy” rating and a $100.00 target price for the company. Royal Bank Of Canada reissued a “sector perform” rating and issued a $80.00 price target on shares of Perrigo Company in a report on Monday, February 27th. Guggenheim reissued a “buy” rating and issued a $125.00 price target on shares of Perrigo Company in a report on Tuesday, February 28th. Jefferies Group LLC set a $71.00 price target on shares of Perrigo Company and gave the stock a “hold” rating in a report on Tuesday, February 28th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $93.00 price target (down from $95.00) on shares of Perrigo Company in a report on Wednesday, March 1st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the company’s stock. Perrigo Company has a consensus rating of “Hold” and a consensus price target of $84.44.
Perrigo Company Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company (NYSE:PRGO).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230503/7824-shares-in-perrigo-company-prgo-acquired-by-rothschild-asset-management-inc.html
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.